Circulating p53 antibody in patients with colorectal cancer - Relation to clinicopathologic features and survival

The presence of serum anti-p53 antibody has been reported to be associated with survival of patients with breast cancer, ovarian cancer, and hepatocel lular carcinoma. To clarify prognostic significance of p53 antibody in colo rectal cancer, serum p53 antibody was measured in patients with colorectal cancer. The 89 patients included 71 with colorectal cancer and 18 with colo n polyp. An enzyme-linked immunosorbent assay was used to detect p53 antibo dies in serum. Clinicopathological parameters such as age, sex, degree of d ifferentiation of cancer, location of tumor, liver metastasis, stage classi fication, Dukes classification, CEA, CA19-9, and immunostaining of p53 and anti-p53 antibody were evaluated as prognostic factors of colorectal cancer . p53 antibody was positive in 18 of 71 (25%) with colorectal cancer, where as it was positive in only 1 of 18 (6%) with colon polyp. The patients with p53 antibody had higher CEA and CA19-9 levels, higher positive rates of p5 3 protein expression in cancer cells, and higher liver metastasis rates. Th e p53 antibody positivity at stage classification I-IIIb/Dukes classificati on A-C was significantly lower than that at stage classification IV/Dukes c lassification D. Overall survival in colorectal cancer patients with p53 an tibody was significantly shorter than in those without p53 antibody. A Cox regression analysis showed that liver metastasis, stage classification, Duk es classification, CA19-9, and p53 antibody were significant prognostic fac tors in colorectal cancer. Serum anti-p53 antibody could serve as one of th e prognostic factors in patients with colorectal cancer.